» Articles » PMID: 35867061

Post-COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection

Abstract

Importance: Little is known about the risk factors for, and the risk of, developing post-COVID-19 conditions (PCCs) among children.

Objectives: To estimate the proportion of SARS-CoV-2-positive children with PCCs 90 days after a positive test result, to compare this proportion with SARS-CoV-2-negative children, and to assess factors associated with PCCs.

Design, Setting, And Participants: This prospective cohort study, conducted in 36 emergency departments (EDs) in 8 countries between March 7, 2020, and January 20, 2021, included 1884 SARS-CoV-2-positive children who completed 90-day follow-up; 1686 of these children were frequency matched by hospitalization status, country, and recruitment date with 1701 SARS-CoV-2-negative controls.

Exposure: SARS-CoV-2 detected via nucleic acid testing.

Main Outcomes And Measures: Post-COVID-19 conditions, defined as any persistent, new, or recurrent health problems reported in the 90-day follow-up survey.

Results: Of 8642 enrolled children, 2368 (27.4%) were SARS-CoV-2 positive, among whom 2365 (99.9%) had index ED visit disposition data available; among the 1884 children (79.7%) who completed follow-up, the median age was 3 years (IQR, 0-10 years) and 994 (52.8%) were boys. A total of 110 SARS-CoV-2-positive children (5.8%; 95% CI, 4.8%-7.0%) reported PCCs, including 44 of 447 children (9.8%; 95% CI, 7.4%-13.0%) hospitalized during the acute illness and 66 of 1437 children (4.6%; 95% CI, 3.6%-5.8%) not hospitalized during the acute illness (difference, 5.3%; 95% CI, 2.5%-8.5%). Among SARS-CoV-2-positive children, the most common symptom was fatigue or weakness (21 [1.1%]). Characteristics associated with reporting at least 1 PCC at 90 days included being hospitalized 48 hours or more compared with no hospitalization (adjusted odds ratio [aOR], 2.67 [95% CI, 1.63-4.38]); having 4 or more symptoms reported at the index ED visit compared with 1 to 3 symptoms (4-6 symptoms: aOR, 2.35 [95% CI, 1.28-4.31]; ≥7 symptoms: aOR, 4.59 [95% CI, 2.50-8.44]); and being 14 years of age or older compared with younger than 1 year (aOR, 2.67 [95% CI, 1.43-4.99]). SARS-CoV-2-positive children were more likely to report PCCs at 90 days compared with those who tested negative, both among those who were not hospitalized (55 of 1295 [4.2%; 95% CI, 3.2%-5.5%] vs 35 of 1321 [2.7%; 95% CI, 1.9%-3.7%]; difference, 1.6% [95% CI, 0.2%-3.0%]) and those who were hospitalized (40 of 391 [10.2%; 95% CI, 7.4%-13.7%] vs 19 of 380 [5.0%; 95% CI, 3.0%-7.7%]; difference, 5.2% [95% CI, 1.5%-9.1%]). In addition, SARS-CoV-2 positivity was associated with reporting PCCs 90 days after the index ED visit (aOR, 1.63 [95% CI, 1.14-2.35]), specifically systemic health problems (eg, fatigue, weakness, fever; aOR, 2.44 [95% CI, 1.19-5.00]).

Conclusions And Relevance: In this cohort study, SARS-CoV-2 infection was associated with reporting PCCs at 90 days in children. Guidance and follow-up are particularly necessary for hospitalized children who have numerous acute symptoms and are older.

Citing Articles

An online survey among convalescents 5 months post SARS-CoV-2 infection in China.

Wang Y, Liu M, Guo Y, Li M, Guo P, He W Biosaf Health. 2025; 6(4):206-215.

PMID: 40078662 PMC: 11894947. DOI: 10.1016/j.bsheal.2024.06.001.


Prevalence and factors of COVID-19 among children in Hunan, China, following the deregulation of epidemic control: an observational study in epidemiology.

Wan L, Liu Y, Tan S, Xiao J, Feng B, Fang J BMJ Open. 2025; 15(3):e089651.

PMID: 40032399 PMC: 11877153. DOI: 10.1136/bmjopen-2024-089651.


A systematic review of post COVID-19 condition in children and adolescents: Gap in evidence from low-and -middle-income countries and the impact of SARS-COV-2 variants.

Putri N, Laksanawati I, Husada D, Kaswandani N, Prayitno A, Triasih R PLoS One. 2025; 20(3):e0315815.

PMID: 40029921 PMC: 11875387. DOI: 10.1371/journal.pone.0315815.


COVID-19 Vaccination and Odds of Post-COVID-19 Condition Symptoms in Children Aged 5 to 17 Years.

Yousaf A, Mak J, Gwynn L, Lutrick K, Bloodworth R, Rai R JAMA Netw Open. 2025; 8(2):e2459672.

PMID: 39992656 PMC: 11851240. DOI: 10.1001/jamanetworkopen.2024.59672.


Postacute COVID-19 fatigue, dyspnea and reduced activity in children and adolescents.

Lin C, Chen K, Wu J, Liu Y, Yen T, Lu C Pediatr Res. 2025; .

PMID: 39900834 DOI: 10.1038/s41390-025-03897-2.


References
1.
Thomson H . Children with long covid. New Sci. 2021; 249(3323):10-11. PMC: 7927578. DOI: 10.1016/S0262-4079(21)00303-1. View

2.
Zhang C, Huang L, Tang X, Zhang Y, Zhou X . Pulmonary sequelae of pediatric patients after discharge for COVID-19: An observational study. Pediatr Pulmonol. 2021; 56(5):1266-1269. PMC: 8012994. DOI: 10.1002/ppul.25239. View

3.
Funk A, Florin T, Kuppermann N, Tancredi D, Xie J, Kim K . Outcomes of SARS-CoV-2-Positive Youths Tested in Emergency Departments: The Global PERN-COVID-19 Study. JAMA Netw Open. 2022; 5(1):e2142322. PMC: 8753506. DOI: 10.1001/jamanetworkopen.2021.42322. View

4.
Blankenburg J, Wekenborg M, Reichert J, Kirsten C, Kahre E, Haag L . Comparison of mental health outcomes in seropositive and seronegative adolescents during the COVID19 pandemic. Sci Rep. 2022; 12(1):2246. PMC: 8831534. DOI: 10.1038/s41598-022-06166-y. View

5.
Carfi A, Bernabei R, Landi F . Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020; 324(6):603-605. PMC: 7349096. DOI: 10.1001/jama.2020.12603. View